UroStream

The 2025 Annual Meeting of the Chinese Urological Association (CUDA), held from June 12 to 15 in the romantic city of Zhuhai, brought together leading experts under the theme “Healthy China, Urology First.” At the conference, Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, delivered a compelling presentation on neoadjuvant therapy for upper tract urothelial carcinoma (UTUC). In an exclusive interview with Oncology Frontier – UroStream, he further discussed his team’s research and practical experience in this evolving field.

At the forefront of surgical innovation, Dr. Qu Fajun (Changzheng Hospital) presented a refined interpretation of the Hood technique using a cutting-edge single-port robotic platform. Aiming to elevate prostate cancer…

At the Pujiang Prostate Cancer Academic Conference, Dr. Kan Gong (Peking University First Hospital) introduced an AI-driven diagnostic workflow that enhances prostate cancer precision care—from refined PSAD calculation to advanced…

Editor’s note: PARP inhibitors (PARPi) have become key agents in the treatment of metastatic castration-resistant prostate cancer (mCRPC), marking the beginning of precision oncology in this field. At the 2025…

At ASCO and EAU 2025, Professor Shouzhen Chen (Qilu Hospital, Shandong University) shared an in-depth overview of molecular subtyping in mCRPC. He emphasized established targets like HRR and MSI-H,…

In a thought-provoking panel discussion, leading Chinese experts Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma tackled several pressing issues in prostate cancer care. The conversation spanned diagnostic…

Editor’s Note: Urothelial carcinoma (UC) is one of the most common malignancies of the urinary system. For early-stage non–muscle-invasive disease, treatment typically involves transurethral resection of bladder tumor (TURBt) followed…

Editor’s note: In recent years, antibody-drug conjugates (ADCs) targeting various molecules and using novel payloads have led to significant breakthroughs in the treatment of metastatic urothelial carcinoma (mUC). The combination…

Editor’s Note: The 2025 Annual Meeting of the Chinese Urological Association (CUDA) was successfully held from June 12 to 15 in the coastal city of Zhuhai. With the theme “Healthy…